German CDMO Rentschler expands biologics capacity with deal for Shire site

German CDMO, which is looking to grow its manufacturing network, is adding a site in the U.S. (Rentschler)

Shire started looking for a buyer for a small biologics manufacturing site in Massachusetts shortly after its buyout of Baxalta two years ago. It has finally made a deal.

German CDMO Rentschler Biopharma, which focuses on biologics development and manufacturing, says it has an agreement to buy the former Baxalta manufacturing site in Milford, Massachusetts. It will be Rentschler's first move into the U.S. 

The 100,000-square-foot facility has about 70 employees and Rentschler spokesperson said they have all be offered jobs. The family-owned Rentschler, which currently has about 850 workers, said it will continue to manufacture products for Shire after the deal closes. Terms of the deal were not disclosed.

RELATED: German CDMO Rentschler expands biologics production capacity

Rentschler, which is looking to expand globally, two years ago added a new facility to its site in Laupheim, Germany, to expand its  capacity, saying it recognized the growing demand for biologics. It invested about  €24 million to add two 3,000-liter stainless steel bioreactors, more than doubling its capacity, and had plans to add 200 jobs.

The sale by Shire comes just after Japan’s Takeda announced it is buying the rare disease drug maker for $58 billion, a deal that is expected to result in more consolidation as Takeda looks for extra cash flow to pay for the deal.

Suggested Articles

Pfizer isn't giving up in biosims. This week, it unveiled launches to three Roche blockbusters, with two already on the market.

Novo Nordisk is betting big on GLP-1 Saxenda in its global obesity push, but England's cost watchdog is unimpressed with the drug's long-term outlook.

Tecentriq didn’t show benefit against simple observation at delaying cancer recurrence or death in patients with muscle-invasive urothelial cancer.